[19] developed Ephrin type-A receptor 3 (EPHA3) tyrosine kinase antibody-decorated, temozolomide butyl ester (TBE)-loaded polylactide-co-glycolide (PLGA) nanoparticles (NPs) to treat GBM via the nose-to-brain route. The gene discussed is EPHA3; the disease is glioblastoma.